Daniel Von Hoff MD FACP

Daniel Von Hoff, MD, FACP

His Leadership Has Led To 3 of 4 Drugs Approved By The FDA For The Treatment of Pancreatic Cancer

Daniel D. Von Hoff, M.D., F.A.C.P. FASCO, FAACR is a Distinguished Professor at the Translational Genomics Research Institute (TGen) in Phoenix, Arizona. He holds the Virginia G. Piper Distinguished Chair for Innovative Cancer Research at HonorHealth Clinical Research Institute and the Margaret Givan Larkin Endowed Chair in Developmental Cancer Therapeutics at Hoag Hospital and Medical Director of Research at McKesson Specialty Health and the Chief Scientific Officer for US Oncology Research specializing in phase I clinical trials. He is also Professor of Medicine at the University of Arizona and at the Mayo Clinic, Scottsdale, AZ and Senior Consultant of Clinical Investigation at the City of Hope.

Dr. Von Hoff’s major interest is in the development of new anticancer agents, both in the clinic and in the laboratory. He and his colleagues were involved in the beginning of the development of many FDA approved agents we now use routinely, including: mitoxantrone, fludarabine, paclitaxel, docetaxel, gemcitabine, irinotecan, nelarabine, capecitabine, lapatinib, vismodegib, nab-paclitaxel, nal-IRI, pexidartinib and others.

His clinical trial work has led o the approval of 3 of the 4 drugs approved by the FDA for treatment of patients with advanced pancreatic cancer. At present, he and his colleagues are concentrating on the development of therapies for patients with advanced pancreatic cancer.

Dr. Von Hoff has published more than 741 papers, 143 book chapters and over 1186 abstracts. Dr. Von Hoff received the  2010  David  A.Karnofsky  Memorial  Award  from the American Society of Clinical Oncology for his outstanding contributions to cancer research leading to significant improvement in patient care and most recently the AACR Distinguished Public Service Award in recognition of  his extraordinary clinical research career and leadership in establishing the AACR/ASCO Methods in Clinical Cancer Research Workshop to educate and train young clinical investigators.

Dr. Von Hoff was appointed to President Bush’s National Cancer Advisory Board in 2004-2010.

Dr. Von Hoff joined the Medical Advisory Board of the Seena Magowitz Foundation in 2014.

He is the past President of the American Association for Cancer Research (the world’s largest cancer research organization), a Fellow of the American College of Physicians, and a member and past board member of the American Society of Clinical Oncology.  He is a founder of ILEX™ Oncology, Inc. (acquired by Genzyme after Ilex had 2 agents, alemtuzumab and clofarabine approved by the FDA for patients with leukemia).

Dr. Von Hoff is founder and the Editor Emeritus of Investigational New Drugs – The Journal of New Anticancer Agents; and, past Editor-in-Chief of Molecular Cancer Therapeutics. He is a co-founder of the AACR/ASCO Methods in Clinical Trial Cancer Research Workshop, which has graduated more than 2100 clinical trial physicians. He is also proud to have been a mentor and teacher for multiple medical students, medical oncology fellows, graduate students, and post-doctoral fellows.

Read More About Dr. Daniel Hoff

Does Dr. Von Hoff Ever Sleep?

Dr. Daniel Von Hoff Named One of Of ASCO’s 50 Oncology Luminaries

Increased Survival in Pancreatic Cancer With Nab–Paclitaxel Plus Gmecitabine

Dr. D. Von Noff is an international recognized physician scientist

OncLive Presents Giants of Cancer Care 

Dr. Von Hoff Has Been Instrumental in the Development  of Life Saving Cancer Therapies

Dr. Von Hoff Receives Inaugural AACR Scientific Achievement Award

Abraxanxe and Gemcitabine For Advance Pancreatic Cancer 

Dr. Von Hoff Named A “Giant of Cancer Care

Three Drug Combo Shrinks Tumors and Improves Pancreatic Cancer Survivorship

TGEn and HonorHealth Research Institute Clinical Trial Report High Rate of Tumor Shrinkage